US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

32.21

-0.4300-1.32%

Post-market: 32.210.00000.00%19:29 EST

Volume:187.06K

Turnover:6.13M

Market Cap:1.56B

PE:-13.63

High:33.96

Open:32.81

Low:31.95

Close:32.64

52wk High:36.51

52wk Low:5.49

Shares:48.41M

Float Shares:22.41M

Volume Ratio:0.50

T/O Rate:0.83%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3625

EPS(LYR):-4.2259

ROE:--

ROA:--

PB:3.22

PE(LYR):-7.62

Loading ...

Overview Company News Filings

Oruka Therapeutics to Present at Major Biotech and Healthcare Conferences

BTIG Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)

Oruka Therapeutics Reports Positive Phase 1 Data for ORKA-002 and Launches EVERLAST-B Trial of ORKA-001

Oruka Therapeutics Announces Positive Interim Phase 1 Data for Orka-002 and Initiation of Everlast-B Trial of Orka-001

THOMSON REUTERS

Oruka Therapeutics - Orka-002 Shows 75-80 Days Half-Life Supporting Twice-Yearly Dosing in Psoriasis

THOMSON REUTERS

Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin

Simply Wall St.

Will Oruka Therapeutics (ORKA) New Director Hire Redefine Its Commercial Strategy Or Simply Refine It?

Simply Wall St.

Oruka Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $75

THOMSON REUTERS

Oruka Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Christopher Nathan Martin

Oruka Therapeutics Appoints Chris Martin to Board as Cameron Turtle Resigns

Press Release: Oruka Therapeutics Announces New Board Member and Board Transition

Kaishan Group's Subsidiary KS ORKA Signs Joint Venture LOI with Hungarian Partner to Advance Geothermal Power Projects

Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

A Fresh Look at Oruka Therapeutics (ORKA) Valuation After Promising Clinical Data and New Financing

Simply Wall St.

Oruka Therapeutics (ORKA) Gets a Buy from BTIG

U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare

Assessing Oruka Therapeutics (ORKA) Valuation Following Promising Data on Next-Generation Psoriasis Antibody

Simply Wall St.

How Oruka’s US$756 Million Share Issue and Annual Psoriasis Therapy Could Shape ORKA’s Investment Outlook

Simply Wall St.

Oruka Therapeutics to Present at Guggenheim Healthcare Innovation Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORKA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORKA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","market":"US","secType":"STK","nameCN":"ORUKA THERAPEUTICS INC","latestPrice":32.21,"timestamp":1771016400000,"preClose":32.64,"halted":0,"volume":187059,"hourTrading":{"tag":"盘后","latestPrice":32.21,"preClose":32.21,"latestTime":"19:29 EST","volume":5258,"amount":169356.37,"timestamp":1771028991552,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.013174019607843129,"floatShares":22408091,"shares":48409232,"eps":-2.3625,"marketStatus":"Market Closed","change":-0.43,"latestTime":"02-13 16:00:00 EST","open":32.81,"high":33.96,"low":31.95,"amount":6129362.627118,"amplitude":0.061581,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.3625,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"listingDate":871012800000,"exchange":"NASDAQ","adjPreClose":32.64,"preHourTrading":{"tag":"盘前","latestPrice":32.83,"preClose":32.64,"latestTime":"09:12 EST","volume":82,"amount":2706.6404199999997,"timestamp":1770991935254,"change":0.19,"changeRate":0.005821,"amplitude":0.029412},"postHourTrading":{"tag":"盘后","latestPrice":32.21,"preClose":32.21,"latestTime":"19:29 EST","volume":5258,"amount":169356.37,"timestamp":1771028991552,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.49503066605390456,"impliedVol":0.6079,"impliedVolPercentile":0.2049},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORKA\",,,,,undefined,":{"symbol":"ORKA","floatShares":22408091,"roa":"--","roe":"--","lyrEps":-4.225857,"volumeRatio":0.49503066605390456,"shares":48409232,"dividePrice":0,"high":33.96,"amplitude":0.061581,"preClose":32.64,"low":31.95,"week52Low":5.485,"pbRate":"3.22","week52High":36.51,"institutionHeld":0.9373,"latestPrice":32.21,"eps":-2.3625,"divideRate":0,"volume":187059,"delay":0,"ttmEps":-2.3625,"open":32.81,"prevYearClose":30.31,"prevWeekClose":33.05,"prevMonthClose":34.23,"prevQuarterClose":30.31,"fiveDayClose":33.05,"twentyDayClose":32.5,"sixtyDayClose":28.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORKA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ORKA","fiscalQuarterEnding":"2025/09","expectedEps":-0.56,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.55},{"market":"US","date":"2024-09-03","symbol":"ORKA","defaultRemindTime":1725370200000,"type":"split","dateTimestamp":1725336000000,"forFactor":12,"toFactor":1,"ratio":12},{"date":"2024-08-29","symbol":"ORKA","amount":1.613,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-08-26","defaultRemindTime":1724938200000,"name":"方舟生物医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-08-28","payableDate":"2024-08-26","currency":"USD","dateTimestamp":1724904000000,"payDate":"2024-08-28"},{"market":"US","date":"2024-08-01","symbol":"ORKA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722484800000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-04-25","symbol":"ORKA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"post","actualEps":-0.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORKA\",market:\"US\",,,undefined,":[{"executeDate":"2024-08-29","recordDate":"2024-08-26","paymentDate":"2024-08-28","value":1.613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORKA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":14,"updateTime":1767762000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ORKA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ORKA","date":"2026-02-13","current":-13.633862,"percent":0.068085,"low":-15.744639,"twenty":-12.717965,"median":-5.287536,"eighty":-4.214018,"high":-2.779284,"avg":-7.859623,"sd":4.24711,"marketCap":1580077332},"quantilePoints":[{"date":"2025-03-14","current":-4.566552,"twenty":-4.600166,"median":-4.533759,"eighty":-4.155287,"marketCap":417087281},{"date":"2025-03-21","current":-4.898591,"twenty":-4.788731,"median":-4.634189,"eighty":-4.465422,"marketCap":447414094},{"date":"2025-03-28","current":-4.898591,"twenty":-4.90187,"median":-4.734621,"eighty":-4.543597,"marketCap":447414094},{"date":"2025-04-04","current":-3.656521,"twenty":-4.90187,"median":-4.68543,"eighty":-4.155287,"marketCap":333969349},{"date":"2025-04-11","current":-3.021139,"twenty":-4.898591,"median":-4.546056,"eighty":-3.567158,"marketCap":275936558},{"date":"2025-04-17","current":-3.529445,"twenty":-4.883833,"median":-4.205819,"eighty":-3.28595,"marketCap":322362791},{"date":"2025-04-25","current":-4.304201,"twenty":-4.810047,"median":-4.25501,"eighty":-3.440082,"marketCap":393125355},{"date":"2025-05-02","current":-4.136132,"twenty":-4.747739,"median":-4.214018,"eighty":-3.521247,"marketCap":377774745},{"date":"2025-05-09","current":-3.996758,"twenty":-4.714945,"median":-4.198946,"eighty":-3.605691,"marketCap":365044972},{"date":"2025-05-16","current":-3.364967,"twenty":-4.682151,"median":-4.136132,"eighty":-3.605691,"marketCap":354187224},{"date":"2025-05-23","current":-3.980336,"twenty":-4.607544,"median":-4.002451,"eighty":-3.625269,"marketCap":418959306},{"date":"2025-05-30","current":-4.215101,"twenty":-4.558354,"median":-4.038702,"eighty":-3.660839,"marketCap":443670043},{"date":"2025-06-06","current":-4.336041,"twenty":-4.541137,"median":-4.079934,"eighty":-3.705732,"marketCap":456399816},{"date":"2025-06-13","current":-4.57792,"twenty":-4.558354,"median":-4.136132,"eighty":-3.769048,"marketCap":481859363},{"date":"2025-06-20","current":-4.261343,"twenty":-4.543597,"median":-4.170639,"eighty":-3.777968,"marketCap":448537309},{"date":"2025-06-27","current":-4.136846,"twenty":-4.523383,"median":-4.154632,"eighty":-3.785238,"marketCap":435433131},{"date":"2025-07-03","current":-4.48188,"twenty":-4.48188,"median":-4.154632,"eighty":-3.808193,"marketCap":471750426},{"date":"2025-07-11","current":-5.004766,"twenty":-4.566552,"median":-4.184867,"eighty":-3.812292,"marketCap":526787975},{"date":"2025-07-18","current":-5.463625,"twenty":-4.701827,"median":-4.197316,"eighty":-3.861483,"marketCap":575086233},{"date":"2025-07-25","current":-5.061679,"twenty":-4.767415,"median":-4.21456,"eighty":-3.877182,"marketCap":532778457},{"date":"2025-08-01","current":-4.834028,"twenty":-4.898055,"median":-4.257786,"eighty":-3.894967,"marketCap":508816530},{"date":"2025-08-08","current":-4.862484,"twenty":-4.898591,"median":-4.281656,"eighty":-3.898524,"marketCap":511811771},{"date":"2025-08-15","current":-5.221398,"twenty":-4.905169,"median":-4.336041,"eighty":-3.910674,"marketCap":561761175},{"date":"2025-08-22","current":-5.148299,"twenty":-5.001209,"median":-4.36364,"eighty":-3.910674,"marketCap":553896518},{"date":"2025-08-29","current":-5.315383,"twenty":-5.050833,"median":-4.460538,"eighty":-3.918873,"marketCap":571872876},{"date":"2025-09-05","current":-5.210955,"twenty":-5.062675,"median":-4.474766,"eighty":-3.936742,"marketCap":560637652},{"date":"2025-09-12","current":-5.621705,"twenty":-5.07235,"median":-4.48188,"eighty":-3.943016,"marketCap":604829531},{"date":"2025-09-19","current":-5.771385,"twenty":-5.152476,"median":-4.546056,"eighty":-3.972962,"marketCap":620933352},{"date":"2025-09-26","current":-5.238803,"twenty":-5.191462,"median":-4.609934,"eighty":-3.980356,"marketCap":563633712},{"date":"2025-10-03","current":-6.676428,"twenty":-5.243928,"median":-4.669033,"eighty":-3.986032,"marketCap":718305289},{"date":"2025-10-10","current":-11.49024,"twenty":-5.309118,"median":-4.714571,"eighty":-3.994896,"marketCap":1236215032},{"date":"2025-10-17","current":-11.944453,"twenty":-5.339054,"median":-4.762887,"eighty":-3.996758,"marketCap":1285083024},{"date":"2025-10-24","current":-12.200791,"twenty":-5.382217,"median":-4.835807,"eighty":-4.005866,"marketCap":1312661989},{"date":"2025-10-31","current":-12.641513,"twenty":-5.468786,"median":-4.862484,"eighty":-4.057038,"marketCap":1360078456},{"date":"2025-11-07","current":-12.717965,"twenty":-5.593858,"median":-4.890941,"eighty":-4.0778,"marketCap":1368303762},{"date":"2025-11-14","current":-11.869655,"twenty":-5.811068,"median":-4.898591,"eighty":-4.08882,"marketCap":1277035540},{"date":"2025-11-21","current":-11.960253,"twenty":-6.69801,"median":-4.937534,"eighty":-4.127114,"marketCap":1306565171},{"date":"2025-11-28","current":-13.338408,"twenty":-7.110152,"median":-4.992317,"eighty":-4.136132,"marketCap":1457117883},{"date":"2025-12-05","current":-13.706211,"twenty":-11.478098,"median":-5.012542,"eighty":-4.13656,"marketCap":1497297545},{"date":"2025-12-12","current":-13.387153,"twenty":-11.950773,"median":-5.056256,"eighty":-4.136846,"marketCap":1462442898},{"date":"2025-12-19","current":-12.474292,"twenty":-12.178774,"median":-5.061679,"eighty":-4.147518,"marketCap":1362719880},{"date":"2025-12-26","current":-14.233544,"twenty":-12.273678,"median":-5.068237,"eighty":-4.154632,"marketCap":1554904531},{"date":"2026-01-02","current":-13.431466,"twenty":-12.335062,"median":-5.068793,"eighty":-4.160323,"marketCap":1467283821},{"date":"2026-01-09","current":-11.698803,"twenty":-12.335062,"median":-5.136174,"eighty":-4.183799,"marketCap":1278003724},{"date":"2026-01-16","current":-14.401935,"twenty":-12.358192,"median":-5.155261,"eighty":-4.187731,"marketCap":1573300040},{"date":"2026-01-23","current":-15.744639,"twenty":-12.45713,"median":-5.171947,"eighty":-4.192073,"marketCap":1719980012},{"date":"2026-01-30","current":-15.624992,"twenty":-12.523037,"median":-5.216176,"eighty":-4.197316,"marketCap":1706909520},{"date":"2026-02-06","current":-13.923348,"twenty":-12.576213,"median":-5.238803,"eighty":-4.205819,"marketCap":1521018069},{"date":"2026-02-13","current":-14.463974,"twenty":-12.717965,"median":-5.287536,"eighty":-4.214018,"marketCap":1580077332}],"updateTime":1771121608430},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORKA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610637866","title":"Oruka Therapeutics to Present at Major Biotech and Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637866","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610637866?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:00","pubTimestamp":1770638422,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL42SCbj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014013.SGD","ORKA","IE00B64PRP62.GBP","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2608848992","title":"BTIG Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848992","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608848992?lang=en_us&edition=fundamental","pubTime":"2026-02-03 10:47","pubTimestamp":1770086825,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a price target of $73.00. According t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2603683932","title":"BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603683932","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603683932?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:13","pubTimestamp":1768302780,"startTime":"0","endTime":"0","summary":"BTIG analyst Julian Harrison maintained a Buy rating on Oruka Therapeutics yesterday and set a price target of $73.00. The company’s shares closed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-their-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-their-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2602514695","title":"Oruka Therapeutics Reports Positive Phase 1 Data for ORKA-002 and Launches EVERLAST-B Trial of ORKA-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514695","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514695?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219225,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc. announced positive interim data from its Phase 1 trial of ORKA-002, a novel biologic candidate for chronic skin diseases, including plaque psoriasis and hidradenitis suppurativa. The Phase 1 trial, which enrolled 24 healthy adult participants, demonstrated that ORKA-002 has a half-life of 75-80 days, supporting potential for twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. The drug was well tolerated at all tested dose levels, with no severe or serious adverse events reported. Additional data from the trial will be presented at an upcoming medical meeting. Oruka Therapeutics also announced that Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 for psoriasis and in the second half of 2026 for hidradenitis suppurativa. Additionally, the first patients were dosed in December 2025 in the EVERLAST-B Phase 2b trial of ORKA-001, with data expected in 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7zM0XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2602751450","title":"Oruka Therapeutics Announces Positive Interim Phase 1 Data for Orka-002 and Initiation of Everlast-B Trial of Orka-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2602751450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602751450?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA4T368Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2602109514","title":"Oruka Therapeutics - Orka-002 Shows 75-80 Days Half-Life Supporting Twice-Yearly Dosing in Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602109514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602109514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA4T368Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2593152439","title":"Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2593152439","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593152439?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:15","pubTimestamp":1766409344,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) shares have been moving after the company added Chris Martin to its board, a commercial veteran whose launch and M&A track record could reshape how investors think about Oruka’s pipeline.\nSee our latest analysis for Oruka Therapeutics.\nThe market seems to be buying into that narrative already, with a 1 day share price return of 13.11% and a 90 day share price return of 104.63%. The 1 year total shareholder return of 51.62% suggests momentum has been building rather...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-valuation-check-after-board-appointm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/oruka-therapeutics-orka-valuation-check-after-board-appointm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2593126287","title":"Will Oruka Therapeutics (ORKA) New Director Hire Redefine Its Commercial Strategy Or Simply Refine It?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593126287","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593126287?lang=en_us&edition=fundamental","pubTime":"2025-12-21 14:16","pubTimestamp":1766297809,"startTime":"0","endTime":"0","summary":"Earlier this month, Oruka Therapeutics announced that director Cameron Turtle resigned from its Board and was replaced by Christopher Martin, a veteran commercial leader who will serve as a Class II director, Compensation Committee Chair, and Audit Committee member through the 2026 annual meeting.\nInvestors may focus on Martin’s track record in preparing multiple first-time drug launches and his recent role at Verona Pharma, which was acquired by Merck for approximately US$10.00 billion...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/will-oruka-therapeutics-orka-new-director-hire-redefine-its","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/will-oruka-therapeutics-orka-new-director-hire-redefine-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2592971340","title":"Oruka Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $75","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592971340?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:35","pubTimestamp":1766050534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO09S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2590154199","title":"Oruka Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Christopher Nathan Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2590154199","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590154199?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:33","pubTimestamp":1765488800,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Christopher Nathan Martin as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLtnfnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Oruka Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Christopher Nathan Martin","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2590968549","title":"Oruka Therapeutics Appoints Chris Martin to Board as Cameron Turtle Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2590968549","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590968549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486874,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc. has appointed Chris Martin to its Board of Directors, replacing Cameron Turtle, DPhil, who resigned effective December 11, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLcgr85N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","ORKA","BK4585","SG9999014039.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2590549965","title":"Press Release: Oruka Therapeutics Announces New Board Member and Board Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2590549965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590549965?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:01","pubTimestamp":1765486860,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Dec. 11, 2025  -- Oruka Therapeutics, Inc.  , a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis , today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025.\"As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka,\" said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. \"Chris's expertise can bring tremendous value to the company as we advance towards late-stage development and think more concretely about how ORKA-001 and -002 could enter the market. We have greatly valued Cameron's contributions on our Board in helping to shape our strategy and direction in the early stages of building our company, and I would like to personally thank him on behalf of our Board for hi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORKA","LENZ","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"1110077724","title":"Kaishan Group's Subsidiary KS ORKA Signs Joint Venture LOI with Hungarian Partner to Advance Geothermal Power Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=1110077724","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110077724?lang=en_us&edition=fundamental","pubTime":"2025-11-27 12:06","pubTimestamp":1764216401,"startTime":"0","endTime":"0","summary":"Kaishan Group Co., Ltd. (300257.SZ) announced that its wholly-owned subsidiary, KS ORKA Renewables Pte Ltd (\"KS ORKA\"), recently signed a Letter of Intent (LOI) with Hungarian company Bölény Zrt...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0196","BK0259","BK4139","BK0117","ORKA","BK0070","300257"],"gpt_icon":0},{"id":"2584994459","title":"Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584994459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584994459?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:35","pubTimestamp":1763559322,"startTime":"0","endTime":"0","summary":"In a report released today, Roger Song from Jefferies maintained a Buy rating on Oruka Therapeutics, with a price target of $45.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-oruka-therapeutics-orka-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORKA"],"gpt_icon":0},{"id":"2584250649","title":"A Fresh Look at Oruka Therapeutics (ORKA) Valuation After Promising Clinical Data and New Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584250649","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584250649?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:20","pubTimestamp":1763364046,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) stock is catching investor attention after the company shared promising Phase 1 results for ORKA-001, suggesting the potential for annual dosing in psoriasis and longer remission. The completion of new financing also strengthens its balance sheet for upcoming trials.\nSee our latest analysis for Oruka Therapeutics.\nMomentum in Oruka Therapeutics stock has clearly accelerated as fresh trial data and new financing caught investors’ attention. The share price is up an...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/a-fresh-look-at-oruka-therapeutics-orka-valuation-after-prom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/a-fresh-look-at-oruka-therapeutics-orka-valuation-after-prom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2583210561","title":"Oruka Therapeutics (ORKA) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2583210561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583210561?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:37","pubTimestamp":1763033864,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a price target of $63.00. The company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oruka-therapeutics-orka-gets-a-buy-from-btig-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2583855979","title":"U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2583855979","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583855979?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:46","pubTimestamp":1763019995,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Abbvie, BristolMyers Squibb, Diversified Healthcare Nov 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL4N3WP0H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HHH","JNJ","FTCI","HTFL","LU2417539215.USD","AMGN","BRBR","LU1974910355.USD","AMN","BCSF","CRMD","GFS","ORKA","BMY","LU0823416689.USD","LU1880398471.USD","LU1046421795.USD","KBDC","ANAB","CCOI","KRRO","AKAM","CSCO","LCID","LPRO","VAC","GLXY","LU1221951046.USD","PRVA","BK4020","LU1221951129.SGD","LEGN","BK4534","KMI","GILD","LU0868494617.USD","ABBV","NXT","CVX","DHC","LU2361045086.USD","ALB","PCH","LWAY","CELC","MRK"],"gpt_icon":1},{"id":"2582840323","title":"Assessing Oruka Therapeutics (ORKA) Valuation Following Promising Data on Next-Generation Psoriasis Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2582840323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582840323?lang=en_us&edition=fundamental","pubTime":"2025-11-10 13:19","pubTimestamp":1762751943,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics (ORKA) has been gaining attention following new data from its investigational psoriasis therapy, ORKA-001. The antibody’s long half-life and convenient dosing profile have sparked discussion among investors and clinicians alike.\nSee our latest analysis for Oruka Therapeutics.\nOruka Therapeutics has seen considerable attention in recent months, with momentum building as shares climbed 13.3% over the past month and a striking 112.6% over the last quarter. Clinical progress...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-following-promis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/assessing-oruka-therapeutics-orka-valuation-following-promis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ORKA"],"gpt_icon":0},{"id":"2582864207","title":"How Oruka’s US$756 Million Share Issue and Annual Psoriasis Therapy Could Shape ORKA’s Investment Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2582864207","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582864207?lang=en_us&edition=fundamental","pubTime":"2025-11-09 05:26","pubTimestamp":1762637189,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics recently closed a shelf registration, issuing 39,425,806 shares of common stock for US$756.19 million.\nA key development supporting this event is the company’s ORKA-001 candidate, which showed a long half-life and promising safety profile in phase 1 studies for psoriasis, potentially enabling once-yearly dosing.\nWe’ll explore how the prospect of annual administration with ORKA-001 could influence Oruka’s investment narrative moving forward.\nUncover the next big thing with...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/how-orukas-us756-million-share-issue-and-annual-psoriasis-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orka/oruka-therapeutics/news/how-orukas-us756-million-share-issue-and-annual-psoriasis-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ORKA","BK4139"],"gpt_icon":0},{"id":"2579745539","title":"Oruka Therapeutics to Present at Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2579745539","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579745539?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:00","pubTimestamp":1761735646,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics Inc., a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, will present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL2KbX0t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","ORKA","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}